← Eichor
Study identifier: NCT07479147 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation

Condition: Ischemic Stroke · Embolic Stroke of Undetermined Source · Patent Foramen Ovale (PFO)  ·  Sponsor: Taichung Veterans General Hospital

PhaseN/A
Planned participants400
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

Patent foramen ovale (PFO) is an important mechanism of embolic stroke of undetermined source (ESUS). Current guidelines recommend PFO closure for high-risk PFO in patients younger than 60 years, and a recent retrospective cohort study from Taichung Veterans General Hospital has shown that closure is effective and safe in older adults; however, the optimal treatment strategy for those \>60 years and direct head-to-head comparisons of PFO closure versus direct oral anticoagulants (DOACs) remain insufficient. Robust evidence from a multicenter study combining prospective and retrospective cohorts is warranted. The SENIOR study is a multicenter observational cohort registry with a combined retrospective and prospective design. The prospective period is from September 15, 2025 to December 31, 2031, and the retrospective period covers January 1, 2013 to September 1, 2025; target sample sizes are 400 (prospective) and 500 (retrospective). We will enroll adults with ESUS and PFO; the prospective arm will focus on patients aged \>60 years with PFO related stroke. Treatments will be assigned as PFO closure, standard-dose DOAC, or antiplatelet agents (if DOAC intolerance) by local principal investigator. The primary outcome is recurrent ischemic stroke or transient ischemic attack. Secondary outcomes include 6-month functional outcome, all stroke, and serial comparison of atrial cardiopathy changes. Safety endpoints include peri-procedural adverse events (including newly-onset atrial …

This description comes directly from the study's public registry record.

Talk to the study team

Chi-Sheng Wang, MD  ·  +886933375721  ·  sam7227632@gmail.com

I-Hui Lee, MD, PhD  ·  +886-4-23592525  ·  ihui_lee@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (3)

Taichung Veterans General HospitalTaichung, TaiwanRecruiting
National Taiwan University HospitalTaipei, TaiwanRecruiting
Taipei Veterans General HospitalTaipei, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07479147